Publication | Closed Access
Getting a lead on Pb<sup>2+</sup>-amide chelators for <sup>203/212</sup>Pb radiopharmaceuticals
25
Citations
42
References
2021
Year
Amide-based chelators DTPAm, EGTAm and ampam were synthesized to investigate which chelator most ideally coordinates [<sup>nat/203</sup>Pb]Pb<sup>2+</sup> ions for potential radiopharmaceutical applications. <sup>1</sup>H NMR spectroscopy was used to study each metal-ligand complex in the solution state. The <sup>1</sup>H NMR spectrum of [Pb(DTPAm)]<sup>2+</sup> revealed minimal isomerization and fluxional behaviour compared to [Pb(EGTAm)]<sup>2+</sup> and [Pb(ampam)]<sup>2+</sup>, both of which showed fewer spectral changes indicative of less static behaviour. The solid-state coordination properties of each complex were also examined from single crystal structures that were studied by X-ray diffraction (XRD). In the solid-state, octadentate DTPAm coordinated Pb<sup>2+</sup> to form an eight-coordinate hemidirected complex; octadentate EGTAm coordinated Pb<sup>2+</sup> forming a ten-coordinate holodirected complex with a bidentate NO<sub>3</sub><sup>-</sup> ion also coordinated to the metal centre; decadentate ampam completely encapsulated the Pb<sup>2+</sup> ion to form a ten-coordinate holodirected complex with a C<sub>2</sub> axis of symmetry. Potentiometric titrations were carried out to assess the thermodynamic stability of each metal-ligand complex. The pM values obtained for [Pb(DTPAm)]<sup>2+</sup>, [Pb(EGTAm)]<sup>2+</sup> and [Pb(ampam)]<sup>2+</sup> were 9.7, 7.2 and 10.2, respectively. The affinity of each chelator for Pb<sup>2+</sup> ions was tested by [<sup>203</sup>Pb]Pb<sup>2+</sup> radiolabeling studies to evaluate their prospects as chelators for [<sup>203/212</sup>Pb]Pb<sup>2+</sup>-based radiopharmaceuticals. DTPAm radiolabeled [<sup>203</sup>Pb]Pb<sup>2+</sup> ions achieving molar activities as high as 3.5 MBq μmol<sup>-1</sup> within 15 minutes, at 25 °C, whereas EGTAm and ampam produced lower molar activities of 0.25 MBq μmol<sup>-1</sup> within 30 minutes, at 37 °C. EGTAm and ampam were therefore deemed unsuitable for [<sup>203/212</sup>Pb]Pb<sup>2+</sup>-based radiopharmaceutical applications, while DTPAm warrants further studies.
| Year | Citations | |
|---|---|---|
Page 1
Page 1